Mitochondrial protein translation is a heightened dependence and therapeutic vulnerability of chemo-refractory triple negative breast cancer

This study identifies OXA1L-dependent mitochondrial protein translation as a critical driver of chemoresistance in triple-negative breast cancer and demonstrates that repurposing the antibiotic tigecycline to inhibit this process effectively sensitizes resistant tumors to chemotherapy.

The Gist

The Big Picture: The "Unkillable" Cancer Problem

Imagine Triple-Negative Breast Cancer (TNBC) as a very aggressive, shape-shifting villain. Doctors usually try to defeat it with a heavy dose of chemotherapy (the "neoadjuvant" treatment) before surgery.

For many patients, this works great. But for about 45% of patients, the cancer doesn't disappear completely. It leaves behind a few "survivor" cells. These survivors are like a ninja squad that has learned to dodge the chemical bullets. Because they survived the first round, they are much harder to kill later, leading to the cancer coming back (relapse) and spreading.

This study asks: What superpower do these surviving cancer cells have that makes them so tough?

The Discovery: The Power Plant Upgrade

The researchers discovered that these "survivor" cancer cells rely heavily on their mitochondria.

• The Analogy: Think of a cell as a factory. The mitochondria are the power plants inside that factory.
• The Twist: Most cancer cells run on a messy, inefficient power source (like a gas generator). But these specific TNBC survivors upgraded their power plants to run on Oxidative Phosphorylation (OxPhos). This is a super-efficient, high-output energy system (like a nuclear reactor) that allows them to repair themselves quickly and survive the chemotherapy attack.

The Key Player: The "Construction Foreman" (OXA1L)

The researchers found that this super-efficient power plant doesn't run on its own. It needs a specific protein called OXA1L.

• The Analogy: Imagine the power plant needs to build its own machinery (the Electron Transport Chain) to generate electricity.
  • The blueprints for some parts come from the cell's main office (the nucleus).
  • The blueprints for other, critical parts come from the power plant's own tiny internal office (the mitochondria).
  • OXA1L is the Construction Foreman. It stands at the assembly line, making sure the parts built inside the power plant are finished correctly and then physically installed into the machine. Without this foreman, the power plant falls apart, and the factory loses its power.

The study found that in the tough, drug-resistant cancer cells, this "Foreman" (OXA1L) is working overtime. It is essential for keeping their super-power plants running.

The Solution: The "Trojan Horse" Antibiotic

Since the cancer cells are so dependent on this specific construction process, the researchers asked: Can we stop the Foreman?

They realized that mitochondria are ancient; they evolved from bacteria. Because of this, they still use a "bacterial-style" assembly line to build their proteins.

• The Analogy: Doctors have a toolbox of antibiotics (like Tigecycline) that are designed to stop bacteria from building their proteins. Usually, these drugs are used to treat infections like sepsis.
• The Strategy: The researchers realized that because the cancer cell's power plant looks like a bacteria, they could use an old-school antibiotic as a "Trojan Horse." They could trick the cancer cell into thinking the antibiotic is just a normal drug, but it actually shuts down the mitochondrial assembly line.

What Happened When They Tried It?

The team tested this idea in the lab and in mice:

1. In the Lab: When they added the antibiotic (Tigecycline) to the cancer cells, it stopped the "Foreman" (OXA1L) from working. The power plants broke down, the cells lost their super-energy, and they became weak.
2. The Combo Attack: When they gave the antibiotic along with the standard chemotherapy (Carboplatin or Docetaxel), the cancer cells couldn't recover. The chemotherapy tried to damage the cells, and the antibiotic prevented the cells from fixing the damage using their power plants.
3. In Mice: They used a model where mice had tumors that had already survived chemotherapy (the "residual" tumors). Giving the antibiotic alone slowed the tumor growth. But giving the antibiotic after the chemotherapy significantly delayed the cancer from growing back.

The Bottom Line

This paper suggests a new way to fight the hardest-to-treat breast cancers:

1. Identify the Weakness: The cancer cells that survive chemo are addicted to a specific mitochondrial protein (OXA1L) to keep their energy high.
2. Repurpose an Old Drug: We don't need to invent a new drug. We can use an existing, FDA-approved antibiotic (Tigecycline) to jam that specific protein.
3. The Result: By turning off the cancer's "super-power," we make the standard chemotherapy work much better, potentially stopping the cancer from coming back.

In short: The cancer survived the first battle by upgrading its engine. The researchers found a way to pour sand in that engine using an old antibiotic, making the cancer vulnerable again.

Technical Summary

1. Problem Statement

Triple-negative breast cancer (TNBC) is an aggressive subtype lacking targeted therapy options for the majority of patients. While neoadjuvant chemotherapy (NACT) is the standard of care, approximately 45% of patients retain residual cancer burden (RCB) post-treatment. These residual tumors are highly resistant to further therapy and correlate with poor relapse-free and overall survival rates. Previous work has established that mitochondrial oxidative phosphorylation (oxphos) is upregulated in chemoresistant TNBC, but the specific molecular mechanisms driving this metabolic adaptation and the associated therapeutic vulnerabilities remain poorly understood. The study aims to identify the specific mitochondrial dependencies that sustain chemoresistance and explore novel strategies to target them.

2. Methodology

The study employed a multi-modal approach combining bioinformatics, molecular biology, and preclinical animal models:

• Bioinformatic & Proteomic Analysis:
  • Analyzed mass spectrometry proteomics data from the CPTAC-TNBC clinical cohort (48 patients, 17 pCR vs. 31 non-pCR) and a large-scale Patient-Derived Xenograft (PDX) cohort (50 models).
  • Performed Gene Set Enrichment Analysis (GSEA) using Reactome and MitoCarta gene sets to identify pathways associated with chemoresistance.
  • Generated a Mitochondrial Ribosome Protein (MRP) signature and analyzed correlations with therapeutic response.
• Cell Line Models:
  • Used human TNBC cell lines (MDA-MB-231, SUM159pt) and non-tumorigenic mammary epithelial cells (MCF10a) as controls.
  • Gene Silencing: Transient siRNA knockdown (KD) of OXA1L (Oxidase (Cytochrome C) Assembly 1-Like), a mitoribosome accessory protein.
  • Drug Treatments: Treated cells with Carboplatin (CRB), Docetaxel (DTX), and repurposed antibiotics Tigecycline (TIG) and Chloramphenicol.
• Functional Assays:
  • Mitochondrial Function: Seahorse XF Analyzer for Oxygen Consumption Rate (OCR/oxphos) and Extracellular Acidification Rate (ECAR/glycolysis).
  • Protein Analysis: Western blotting for Electron Transport Chain (ETC) complexes (I–V), Blue Native PAGE (BN-PAGE) to assess supercomplex (SC) formation, and ATP quantification.
  • Translation Imaging: Mito-FUNCAT (Fluorescent Non-Canonical Amino acid Tagging) to visualize and quantify nascent mitochondrial peptide synthesis in real-time.
  • Genomic Analysis: qPCR for mtDNA/nDNA ratios and mitochondrial RNA levels.
• In Vivo Models:
  • PDX Spheroids: Ex vivo treatment of spheroids derived from three TNBC PDX models (PIM001-P, BCM-4272, BCM-7649).
  • Orthotopic Mouse Models: Treatment of residual PIM001-P tumors in SCID/bg mice with TIG monotherapy or in combination with CRB/DTX to assess tumor regrowth delay.

3. Key Contributions

• Identification of OXA1L as a Driver: The study identifies OXA1L as a critical, previously uncharacterized driver of chemoresistance in TNBC. OXA1L is essential for both the termination of mitochondrial translation and the insertion of nascent proteins (both mtDNA- and nDNA-encoded) into the inner mitochondrial membrane (IMM).
• Mechanistic Link to Chemoresistance: The authors demonstrate that chemoresistant TNBC cells rely on OXA1L-mediated mitochondrial translation to maintain high levels of ETC supercomplexes (respirasomes) and oxphos, which are required for survival under chemotherapy stress.
• Therapeutic Repurposing: The study validates the repurposing of the FDA-approved antibiotic Tigecycline (TIG) as a potent inhibitor of mitochondrial translation in TNBC. TIG disrupts the pro-survival mitochondrial adaptations induced by chemotherapy.
• Therapeutic Window: Evidence suggests a selective dependency on mitochondrial translation in TNBC cells compared to normal mammary epithelial cells (MCF10a), indicating a potential therapeutic window.

4. Key Results

• Proteomic Signatures: Analysis of CPTAC and PDX datasets revealed that mitochondrial translation-related pathways (specifically "mitochondrial translation termination") and OXA1L protein levels were significantly enriched in chemoresistant (non-pCR) tumors compared to sensitive (pCR) tumors. OXA1L levels increased further upon on-treatment biopsies.
• OXA1L Function:
  • KD of OXA1L in TNBC cells reduced levels of all five ETC complexes (both mtDNA- and nDNA-encoded subunits), disrupted respirasome (supercomplex) formation, and significantly decreased OCR and ATP production.
  • OXA1L KD abolished the chemotherapy-induced elevation of OCR (metabolic adaptation) and sensitized cells to both CRB and DTX.
  • In contrast, OXA1L KD had minimal impact on non-tumorigenic MCF10a cells, confirming a tumor-selective vulnerability.
• Tigecycline Efficacy:
  • Translation Inhibition: Mito-FUNCAT imaging confirmed that TIG potently inhibits mitochondrial nascent peptide synthesis (reducing translation by ~86% at high doses and ~36% at IC50).
  • Metabolic Disruption: TIG treatment reduced ETC protein levels, disrupted supercomplex assembly, and abolished the CRB-induced OCR boost.
  • Synergy: Combining TIG with CRB or DTX significantly enhanced cell death and reduced tumor viability in vitro compared to chemotherapy alone.
  • In Vivo: In the PIM001-P orthotopic model, TIG monotherapy slowed tumor growth. Crucially, administering TIG to residual tumors (after CRB/DTX treatment) significantly delayed tumor regrowth compared to chemotherapy alone.
• Safety & Limitations: While TIG showed efficacy, high-dose intraperitoneal administration in mice caused peritonitis, suggesting that dose optimization or alternative delivery routes are necessary for clinical translation.

5. Significance

This study provides a novel mechanistic framework for understanding chemoresistance in TNBC, shifting the focus from general mitochondrial metabolism to the specific machinery of mitochondrial protein translation.

• New Target: It highlights OXA1L and the mitoribosome as critical, druggable vulnerabilities in residual TNBC.
• Clinical Strategy: It offers a compelling rationale for repurposing FDA-approved antibiotics (like Tigecycline) to sensitize chemoresistant TNBC to standard chemotherapy. This approach could potentially improve outcomes for the large subset of patients who fail to achieve a complete pathologic response to NACT.
• Future Directions: The findings justify further investigation into TIG-based combination therapies, the identification of biomarkers for patient selection, and the optimization of dosing regimens to mitigate toxicity while maintaining efficacy in immune-competent models.